Niagen Bioscience, Inc. — Director's Dealing 2019

Nov 15, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2019-11-14

Reporting Person: Fried Robert N (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-14	Common Stock	P	10000	$3.09	Acquired	1444315	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12746	Indirect

Footnotes

F1: Previous Form 4's disclosing the Reporting Person's beneficial ownership inadvertently overstated the number of shares directly beneficially owned by the Reporting Person by 2,012 shares. The number of shares is corrected in this Form 4.

F2: 6,745 shares held by Jeremy Fried and 6,001 shares held by Benjamin Fried, who are both sons of Robert Fried. The number of shares reflected as indirectly beneficially owned reflects an additional two shares inadvertently omitted from the Reporting Person's prior Form 4's.